EPOR and myeloproliferative neoplasm: In JAK2V617F-driven MPN models, including Ba/F3-JAK2V617F and Ba/F3-EPOR-JAK2V617F disease models, oral FM at doses of 15, 30, or 45 mg/kg twice a day could dose-dependently inhibit splenomegaly and improve survival.